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Review Article
Whole genome sequencing of breast cancer
MARIA ROSSING,1 CLAUS STORGAARD SØRENSEN,2 BENT EJLERTSEN3 and FINN CILIUS
NIELSEN1
1Centre for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen; 2Biotech
Research and Innovation Centre, University of Copenhagen, Copenhagen; and 3Danish Breast Cancer
Cooperative Group & Department of Clinical Oncology Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark
Rossing M, Sørensen CS, Ejlertsen B, Nielsen FC. Whole genome sequencing of breast cancer. APMIS 2019;
127: 303–315.
Breast cancer was the ﬁrst to take advantage of targeted therapy using endocrine therapy, and for up to 20% of all
breast cancer patients a further signiﬁcant improvement has been obtained by HER2-targeted therapy. Greater insight
in precision medicine is to some extent driven by technical and computational progress, with the ﬁrst wave of a true
technical advancement being the application of transcriptomic analysis. Molecular subtyping further improved our
understanding of breast cancer biology and has through a new tumor classiﬁcation enabled allocation of personalized
treatment regimens. The next wave in technical progression must be next-generation-sequencing which is currently pro-
viding new and exciting results. Large-scale sequencing data unravel novel somatic and potential targetable mutations
as well as allowing the identiﬁcation of new candidate genes predisposing for familial breast cancer. So far, around
15% of all breast cancer patients are genetically predisposed with most genes being factors in pathways implicated in
genome maintenance. This review focuses on whole-genome sequencing and the new possibilities that this technique,
together with other high-throughput analytic approaches, provides for a more individualized treatment course of breast
cancer patients.
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Cancer is a disease of the genome and enormous
eﬀorts are directed towards understanding of this
heterogeneous collection of diseases (1). The expan-
sion of our insight in the cancer genomes is mostly
driven by the rapid development in sequencing
technologies all the way from the early identiﬁca-
tion of oncogenes and tumor suppressors to the full
annotation of the most common cancers resulting
in the so called genomic landscape of cancer (2, 3).
Determining the genomic landscape of cancers is an
ongoing process supported by The Cancer Genome
Atlas (TCGA) dataset which comprises genomic
data from >10 000 thousands of tumor samples,
providing researchers with a comprehensive catalog
of the key genomic changes in more than 30 types
of cancer (4). The major advances in sequencing
technologies followed by the development of com-
putational tools have enabled analyses like whole-
exome sequencing (WES), RNA-sequencing (RNA-
seq) and whole-genome sequencing (WGS) to be
implemented in the routine clinical setting, hereby
supporting the emerging clinical relevance of geno-
mics in cancer medicine as well as for other diseases
(5). The cancer genome is somewhat dynamic, and
each cancer evolves with the accumulation of sev-
eral types of somatic mutations, copy number alter-
ations, epigenetic factors, and structural variants.
These changes can occur in a predisposed genetic
background like the hereditary cancers which again
cause diverse patterns for the individual tumor gen-
ome.
Thus, accepting the fact that cancer is a genomic
disease and combining this with the growing
insights in targeted therapies, the way for precision
oncology is being founded. Precision oncology is
based on the theory that the examination of both
the patients’ genome and the tumor genome will
direct the clinician to the targeted drug, expected toReceived 1 October 2018. Accepted 16 December 2018
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be eﬀectual (6). With the implementation of several
FDA-approved HER2-targted therapies, breast
cancer was one of the earliest cancers where imple-
menting targeted therapies have shown a prolonged
survival in patients whose tumors are driven by this
tyrosine kinase activation (7). Thus, more than
15% of breast cancer patients follow a scheme of
targeted therapy, though there is still room for test-
ing and implementation of precision oncology for
these patients. In line with this, a recent compre-
hensive whole-genome-based study of both the pri-
mary, the locally relapsed, and the metastatic
breast cancer showed that cell clones seeding metas-
tasis or relapse disseminate late from the primary
tumors, but continue to acquire mutations, mainly
within the same pathway as the primary tumor (8).
However, Yates et al., found that most distant
metastasis acquired new driver mutations, including
clinically actionable alterations and mutations,
which is highly relevant for the implementation of
genome-driven oncology with the aim of improving
the dismal survival of metastatic breast cancer
patients.
BREAST CANCER
Breast cancer is the most common malignancy
among females, and together with lung and colorec-
tal cancers, among the three most common cancers
worldwide (9). In 2012 approximately 1.7 million
women were diagnosed with breast cancer world-
wide, and breast cancer accounts for nearly a third
(29%) of all new cancers in women. In women
under the age of 50, breast cancer is the leading
cause of cancer death, but in elder women it is sur-
passed by lung cancer as the most frequent cause of
death. Overall mortality rates are decreasing
although the rates vary greatly worldwide and are
the leading cause of cancer death in the less devel-
oped parts of the world. The incidence of breast
cancer in Denmark is around 4700 new cases per
year, and all though mortality rate has decreased
mostly attributable to early detection via screening
programs and advanced and eﬃcient therapies,
breast cancer still causes 1100 deaths per year;
being the second cause of cancer death also in Dan-
ish women (10).
The diagnostic procedures of breast cancer
include clinical examination, breast imaging usually
comprising mammography and ultrasound, core-
needle tumor biopsy for histopathology with bio-
marker assessment, and assignment of intrinsic sub-
type by molecular genetic analysis (see separate
paragraph on molecular subtypes; 11). Based on a
clinical risk assessment, presence of comorbidities
and patient preferences, a treatment recommenda-
tion is for most patients reached by the multidisci-
plinary team using the biomarker tumor proﬁle of
each patient. Algorithms in combination with risk
factors have been developed for clinical risk assess-
ment of recurrence and have for Danish breast can-
cer patients been extended to allow calculation of a
prognostic standard mortality rate (SMR) index
(PSI) algorithm based on a comprehensive study of
>6500 postmenopausal patients with ER positive
high-risk breast cancer (12, 13). Early breast cancer
without distant metastasis (Stage I + II) is a possi-
ble curative disease with breast conserving surgery
in combination with systematic therapy being the
standard of care (14). In brief, luminal-like, ER+ -
patients are treated with either endocrine therapy
alone, or in combination with chemotherapy. If
tumors are HER2+, trastuzumab is added. For
patients with triple-negative tumors, standard sys-
temic chemotherapy consists of anthracyclines and
taxanes (15).
Neoadjuvant chemotherapy (NACT) – e.g.
chemotherapy initiated before breast cancer sur-
gery – is widely used as a standard of care to
reduce surgical morbidity of the breast and axilla
(16, 17). A recent meta-analysis substantiated that
NACT results in higher rates of breast-conserving
therapy without comprising the risk distant recur-
rence, breast cancer survival, or overall survival
(18). However, uncertainty remains regarding the
extend of axillary lymph node assessment and tar-
get of radiotherapy after NACT. Targeted therapy
directed by tumor proﬁle is a cornerstone in the
NACT – setting where a complete pathological
response and long-term outcome is superior to the
HER2-positive or the ER-negative and HER2-nor-
mal tumors in comparison to the luminal breast
cancers for which the response to NACT is more
unclear (19).
MOLECULAR SUBTYPES
Transcriptome analysis enables classiﬁcation of
breast tumors into intrinsic molecular subtypes
which are biologically distinct entities with speciﬁc
prognostic and therapeutic features (20–25). The
pivotal studies proposed ﬁve subclasses: (i) the ER-
receptor positive and human epidermal growth fac-
tor receptor 2 (HER2)-receptor negative tumors
i.e., luminal A (lumA), luminal B (lumB) and nor-
mal breast-like subclass, (ii) the HER2-receptor
positive tumors: HER2-like subclass, and (iii) the
ER- and HER2-receptor negative tumors called the
basal-like (basL) subclass. Four of the subclasses
can be distinguished by a 50-gene molecular
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classiﬁer (PAM50) which has been developed as a
commercial FDA approved platform (ProsignaVR;
26). This was followed by the 70-gene signature;
MammaPrint, which together with a clinical risk
evaluation, showed promising results for predicting
the low-risk cancers that may omit chemotherapy
(27). In line with this, a comprehensive, multicenter
analysis, TAILORx, freshly showed that the 21-
gene recurrence-score assay (Oncotype DX, Geno-
mic Health) providing prognostic information in
hormone-receptor–positive breast cancer in combi-
nation with the 21-gene-signature, can direct
patients with either a very low score to omit
chemotherapy or patients with a high score to
enroll for chemotherapy (28). However, for most
patients (71%) who were assigned with a mid-range
recurrence score, the TAILORx-study could not
clarify whether disease-free survival or overall sur-
vival was correlated was patients who underwent
treatment with chemotherapy or not; this based on
9 years of follow-up. Recent taxonomies optimized
the subclasses by applying integrative genomic anal-
ysis and Guedj et al. reﬁned the subclasses by intro-
ducing six stable molecular subtypes based on
genomic rearrangement and the expression of 256
transcripts (29, 30). However, a comprehensive
genomic study integrating both genetic and epige-
netic alterations concluded that breast cancers, in
addition to the intrinsic subtypes and clinical
heterogeneity, can be explained by structural vari-
ants deﬁning subclusters within the subtypes (31).
Subsequent studies into deﬁning subclusters of sub-
types has resulted in several new signatures for
identifying speciﬁc somatic and pathway-based sub-
clusters among the intrinsic subtypes (32–36). For
example, Lehmann et al., identiﬁed six subclusters
among the triple-negative breast cancers; two basal-
like (BL1 and BL2), an immunomodulatory (IM), a
mesenchymal (M), a mesenchymal stem-like (MSL),
and a luminal androgen receptor (LAR) subtype.
In addition, 17 pathway-driven subclusters were
suggested by Gatza et al., hereby linking the
heterogeneity to tentative therapeutic strategies. In
many institutions genomic analysis has in recent
years become a part of the standard of care for
most breast cancer patients. It is well-established
that the biological hallmark of luminal A subtype
is low proliferation, high expression of the ESR1
gene and a favorable clinical outcome (37). Since
2011, the St Gallen international expert consensus
panel has recommended merely endocrine therapy
in patients with luminal A disease (15, 38).
Attempts have been made indirectly to approximate
luminal A – like subtype using IHC biomarkers –
ER- and PGR-positive, HER2-negative and
low Ki67 protein staining (39, 40). However,
classiﬁcation with only four biomarkers does not
entirely recapitulate the intrinsic subtype of breast
cancer (37). From 2017, DBCG recommended
molecular subtyping for all patients at intermediate
risk, and a recent study showed the beneﬁts of
applying up-front routine subtyping of all early
breast cancers, hereby identifying both high and
low risk patients (41).
FROM SANGER TO WHOLE-GENOME
SEQUENCING
Sequencing of nucleic acids is a method for deter-
mining the exact order of each nucleotide (C, G, T
and A for DNA sequence and C, G, U and A for
RNA sequence). The order of these nucleotides in a
polynucleotide string is what ﬁnally gives the hered-
itary and biological codes for all human life.
Human DNA consists of about 3 billion nucleo-
tides, and more than 99% of those are identical in
all people. Thus, science, including medical human
research, is conditioned by the ability to determine
the order of nucleotides by sequencing. Or as the
double Nobel laureate Frederick Sanger has said it
once in a more modest quote: ‘. . .knowledge of
sequences could contribute much to our under-
standing of living matter.’ (42). In 1953 Watson
and Crick determined the three-dimensional struc-
ture of the DNA double helix which revolutionized
understanding of science (43). However, the ability
to decode the order of nucleotides or sequence were
time-consuming and labor-intensive until 1977,
where the establishment of the Sanger sequencing
method took place; Selective incorporation of
chain-terminating dideoxynucleotides by DNA
polymerase during in vitro DNA replication (44,
45). Like previous sequencing techniques based on
step-by-step lengthening of sequencing and labeling
of the ﬁnal nucleotide, Sanger sequencing outper-
formed them all due to the precision, robustness
and usability of the chain-termination method,
which made the Sanger technique the most widely
used method in more than two and a half decades.
Automation of the Sanger sequencing method
became a reality in 1986 when Applied Biosystems
launched the automated DNA sequencing instru-
ment where, although still based on the Sanger
method, each nucleotide was now labeled with a
ﬂuorescent dye and allowing a read out of speciﬁc
nucleotides by color (46). Also, the Applied
sequencing instrument enabled 24 samples to run at
the same time and generated sequencing data faster
and cheaper than ever before. This automated San-
ger technique, also known as ‘ﬁrst-generation
sequencing’, allowed one of the largest projects in
© 2019 The Authors. APMIS published by John Wiley & Sons Ltd
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human science; ‘The Human Genome project’. The
Human Genome project set out to sequence every
human chromosome with the objective to advance
knowledge of human biology and improve medi-
cine. After years of planning, the project was for-
mally launched in 1990, and after a 13-year-long
endeavor the project completed in 2003, 2 years
ahead of schedule (47, 48). It still remains the
world’s largest collaborative biological project with
a budget of $3 billion (49).
Following the complete sequencing and mapping
of the 24 human chromosomes, the demand for
sequencing increased rapidly, thus calling for a more
low-cost and high-throughput technique. This calling
motivated the development of second-generation
sequencing, also known as next-generation sequenc-
ing (NGS), where pyrosequencing plays a major role.
The pyrosequencing technique, pioneered by Pal
Nyren and colleagues (50, 51) was still, like the San-
ger’s dideoxy, a sequence-by synthesis’ (SBS) tech-
nique, as they both require a direct action of DNA
polymerase to produce the reading output. The
pyrosequencing method is based on detecting the
activity of the DNA polymerase with luminescence,
hence allowing sequencing a single strand of DNA
by synthesizing the complementary strand, one base
pair at a time. Each nucleotide is sequentially washed
through the system over the template DNA aﬃxed
to a solid phase. Light is produced only when the
nucleotide solution complements the ﬁrst unpaired
base of the template and the order of solutions which
produce the luminescence permits the determination
of the sequence of the template. The ﬁrst major suc-
cessful commercial NGS platform, the 454 sequencer
was based on the concept of pyrosequencing tech-
nique and mass parallelization of sequencing reac-
tions, greatly increasing the amount of DNA that
can be sequenced in one run (52). Several parallel
sequencing techniques followed upon the success of
the 454 sequencer where the Solexa method of
sequencing, acquired by Illumina in 2006, is the most
important and ‘short read’ sequencing platform (53).
In short, template DNA is fragmented and end-
repaired with poly-A tails to ensure the ligation of
adaptors. The adapter oligonucleotides are comple-
mentary to the ﬂow-cell anchors. Adapter-modiﬁed,
single-stranded DNA is added to the ﬂow cell and
immobilized by hybridization. Bridge ampliﬁcation
generates clonally ampliﬁed clusters that are dena-
tured and cleaved, and sequencing can be initiated
with addition of primers, polymerase and the four
reversible dye terminators, followed by imaging and
recording of ﬂuorescence. When recording of the one
cycle is completed, ﬂuorescence and terminators are
removed, and the next cycle of synthesis is directly
initiated.
Targeted sequencing and gene-panels are widely
used when predeﬁned genes are to be sequenced
and if coverage need to be high, for instance to
identify low-frequency tumor-drives. The actual
sequencing process is identical to the one described
above, however the region of interest is captured by
initial hybridization of a library of biotinylated
RNA oligos predesigned to speciﬁc genomic regions
(e.g. gene-panel) using magnetic beads, ﬂowed by
PCR ampliﬁcation. It is often argued that targeted
sequencing is preferable if the suspected disease or
condition has already been identiﬁed, due to aﬀord-
able costs and higher coverage yield as well as
reduced sequencing time (54). However, it may be
reasonable to question this presumption, since it
holds some frauds; for instance, sequencing is often
used to conﬁrm a tentative diagnosis, and often,
variants in the suspected genes associated with the
most likely diagnosis are not identiﬁed, resulting in
another targeted gene panel or a broader screening
method like WES or WGS. Thus, choosing targeted
gene-panel may indeed increase the time until a
causative genetic diagnosis is made, as well as the
costs, which would have been reduced if the geno-
mic approach had been the ﬁrst and only platform
chosen (55–57). Other arguments for working
towards reducing the use of gene-panels and con-
vert to WGS as the primary choice, is that the
sequencing data can be remapped and reanalyzed
at a later stage, when new genetic associations are
identiﬁed; moreover, the data together with the
patients phenotype enables research in a speciﬁc
disease and will lead to the identiﬁcation of new
disease associated candidate genes without further
laboratory costs. Interestingly, when comparing
sample preparation time in the laboratory, the pre-
capture-step necessary for gene-panels exceeds the
non-capture technique used for WGS, both in time
and hands-on (58).
Whole-exome-sequencing is also a result of a
pre-capture-step, this time of all coding exons of
the genome, allowing a sequential screen of the
exome. In contrast, WGS does not include a cap-
turing step, since it is the entire genome that is
intended for sequencing; both coding and non-cod-
ing. This fundamental diﬀerence which may best be
illustrated by a raw sequence output (Fig. 1),
greatly aﬀects the downstream applications. WGS
provides an incomparable complete coverage of the
exome thus, WGS is simply the better WES (59).
As such, and with costs declining and with the
appropriate in silico panels, WGS has the potential
to entirely replace WES and other techniques that
involves capturing of target sequences. In addition,
a wide range of WGS data applications, like
insertion-deletions, copy-number variation (CNV),
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intronic deletions, structural variation and repeti-
tive DNA element, substantiates why this sequenc-
ing platform is superior to WES. It is so far not
possible to interpret the signiﬁcance of most of the
additional ﬁndings from WGS but then only
through continuous sequencing studies, the knowl-
edge database will expand and enable implementa-
tion of precision medicine in a clinical setting.
However, since average coverage of a WGS is
around 30–409, WGS is not optimal for identiﬁca-
tion of mosaicism or other low-frequent variants
e.g. tumor-drivers. For these purposes, a targeted
gene-panel with a minimum of 5009 is more suit-
able. The cost of a WGS opposed to WES and
gene-panels is a major concern. The price of
sequencing is constantly declining and at present
time a WGS costs less than $1.5K (60). The need
for data storage, curation and bioinformatic pro-
cessing is substantial if WGS-analysis is imple-
mented as a routine genetic test (61, 62).
Consequently, most western countries are launching
national initiatives for large-scale whole-genome-
sequencing projects where essential computer- and
man-power is centered. Obviously, the long-term
impact on health economics is not yet understood.
Discussions about how to manage the risk of iden-
tifying incidental genomic ﬁndings have emerged as
one of the more contentious issues in the clinical
application of genomic sequencing (63, 64). The
subject is to vast to review in the present context,
however the key elements that the discussions has
brought is the transition of incidental to secondary
ﬁndings and the patients right to ‘option out’ on
secondary ﬁndings. The American College of Medi-
cal Genetics and Genomics have recently updated
their recommendations on how to address sec-
ondary ﬁndings in a clinical setting, hereby enabling
consensus amongst sequencing laboratories (65).
The basic laboratory workﬂow and downstream
data pipeline and various applications of WGS will
be addressed in the following.
An overview of the laboratory workﬂow for gener-
ating WGS sequencing results is shown in Fig. 2 and
is described only for the commonly applied Illumina
protocol. Genomic DNA puriﬁed from either whole
blood or tumor is prepared for library by using
Nextera DNA Flex Library Preparation Kit with dual
indexes. In brief, 10–500 ng of genomic DNA is used
as input for the on-bead tagmentation step, followed
by a limited PCR ampliﬁcation and bead clean-up of
the WGS DNA sequencing library. Sequencing can
be readily performed as 2 9 150 bp paired-end
sequencing on a NovaSeq6000 instrument. Raw fastq
ﬁles are mapped to the hg19/GRCh37 human refer-
ence genome using BWA-MEM v0.7.12 (Li, 2013)
software. Quality thresholds for the sequencing are
>30-fold average sequencing depth and >98% of the
genome sequenced at least 10-fold. Alignment ﬁle pre-
processing and germline variant calling is performed
by GATK v3.8.0 using Best Practices guidelines (66).
For clinical implications and from sample to clinical
reporting, the entire laboratory workﬂow and data
processing can be completed in less than a week,
depending on the downstream manual and medical
variant classiﬁcation. Preprocessed WGS data can be
used to identify for structural variants e.g. CNVs and
fusion genes or CNVs (59, 67, 68). Furthermore,
WGS data enables de novo assembly, which is an
alternative way of variant calling, since it does not
map to a reference genome, in other words, the vari-
ant caller does not assume any normal positions; thus,
de novo assembly allows ‘wrong’ reads which may
reﬂect insertions, inversions or translocations (69, 70).
It should be noted, that if DNA originates from
tumor tissue the standard algorithm for data process-
ing and variant calling does not explicit consider
tumor impurity or intra-tumor-heterogeneity. So far,
estimation of tumor content and identiﬁcation of clo-
nal somatic aberrations require high-coverage
sequencing, which is not the case for WGS data where
coverage is limited (30–409). Comparative studies
clearly show that tolls developed for high-sequence
coverage data are not suitable for WGS data (71).
Accordingly, bioinformatic tools for deconvolution of
genomic low-coverage data are emerging (61, 72).
HEREDITARY BREAST CANCER
One out of every seven women diagnosed with
invasive breast cancer will have a close relative
(mother, sister, or daughter) also diagnosed with
Fig. 1. BRCA1 gene sequence alignments from the same patient by WGS (top) and WES (bottom). The coverage span of
the entire genome in this sample’s gene was from 0–97 and the entire exome 0–370. WES, whole-exome sequencing; WGS,
whole-genome sequencing.
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the disease. Pathogenic variants in the two major
breast cancer susceptibility genes BRCA1 and
BRCA2 may explain 15% of increased risk of
breast cancer among female relatives of breast can-
cer patients. Germline variants in several other sus-
ceptibility genes also confer a high risk of breast
cancer, including pathogenic variants in ATM,
BARD1, BLM, BRIP1, CDH1, CHEK2, PALB2,
PMS2, FAM175A, FANCC/-M, and RAD51B/-C/-
D as well as the more syndromic predisposing
genes; TP53 (Li–Fraumeni syndrome), PTEN
(Cowdens disease), STK11 (Peutz-Jeghers syn-
drome), NF1 (Neuroﬁbromatosis), and CDH1
(Hereditary diﬀuse gastric cancer syndrome). Large
panels of breast cancer susceptibility genes have
become widely available (73). Identiﬁcation of
pathogenic BRCA1 and BRCA2 variants is rou-
tinely used to predict risk of breast- and ovarian
cancer and guide the use of risk reducing surgery,
thus upfront genetic screening of all new breast
cancer patients enables a more tailored surgical
procedure (74–77). Hence, the meta-analysis by Li
et al., recently substantiated the signiﬁcant
decrease in overall mortality for patients with
pathogenic BRCA1 or BRCA2 variants undergoing
contralateral prophylactic mastectomy as part of
the standard breast cancer intervention. Adjuvant
chemotherapy is not recommended to all patients
with ER-positive and HER2-normal breast cancer
but may in women with germline pathogenic
BRCA1 or BRCA2 variants confer a distinct sur-
vival beneﬁt (75, 78). Furthermore, platinum-based
chemotherapy has in the neoadjuvant and meta-
static setting been superior to conventional anthra-
cycline and taxane based regimens (79). Finally,
targeting impaired BRCA1 or BRCA2 by poly
ADP ribose polymerase-inhibitors (PARPi) is
approved for metastatic breast cancer in women
with germline pathogenic BRCA1 or BRCA2 vari-
ants (80, 81). Accordingly, up-front screening for
BRCA1 and BRCA2 variants is increasingly oﬀered
to patients at the diagnosis of breast cancer and
may be completed in less than a week (41).
National consensus on breast cancer panel testing
is emerging and may result in clinical utility of a
wider range of germline variants (82). It is evident,
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that more breast cancer predisposing genes will
occur and for this purpose, an international screen-
ing program was established to assemble the
sequencing data and collaborating on identifying
and validating new candidate breast cancer
genes (83).
BREAST CANCER AND GENOME
MAINTENANCE
Pathogenic variants in BRCA1 and BRCA2 predis-
pose to hereditary breast and ovarian cancer
(HBOC), but only 15–25% of HBOC cases can be
ascribed to either of the genes. Recently, exome
sequencing has uncovered a substantial locus
heterogeneity among aﬀected families without
BRCA1 and BRCA2 pathogenic variants and in the
same way as BRCA1 and BRCA2 the novel puta-
tive HBOC susceptibility genes are involved in gen-
ome stability pathways such as homologous
recombination repair, and to a minor extent mis-
match repair (MMR) and interstrand cross-link
repair, Fig. 3 (84). DNA double-strand breaks
occurring during DNA replication are frequently
corrected by homologous recombination repair
(HRR). In principle, HRR is an error-free DNA
repair pathway, because it employs the intact sister
chromatid as template for the repair reaction. The
DNA double-stranded ends cannot be used in
HRR, because such DNA cannot align with the
correct corresponding DNA sequence of the sister
chromatid. Thus, the DNA ends are processed to
single-stranded DNA ends before BRCA2 loads
RAD51 onto the ssDNA end. The RAD51-coated
DNA end then searches and anneals with the corre-
sponding sister chromatid DNA sequence (85).
Whereas BRCA2 has a very well-deﬁned role in
HRR with RAD51, the role of BRCA1 is not
entirely understood. BRCA1 interacts with a wide
range of proteins and may simply function as
recruitment scaﬀold. Moreover, BRCA1 haploin-
suﬃciency may lead to an inadequate response to
replication stress, thereby increasing the risk of
cancer (86).
Additional factors such as PALB2, ATM,
BARD1, BRIP1, FAM175A, NBN, MRE11, BLM,
and RAD51 paralogs (RAD51B, RAD51C,
RAD51D, XRCC2, and XRCC3) are also neces-
sary for HRR (84–86). PALB2 stabilizes BRCA2,
and RAD51 paralogs are important for formation
of functional RAD51-ssDNA ends (85). BARD1
heterodimerizes with BRCA1 which has a protein
stabilizing impact on BRCA1 (87). BARD1,
PALB2, and RAD51B variants have been identiﬁed
in breast cancer families, whereas truncating
RAD51C and RAD51D variants are mainly found
in families with ovarian cancer or breast and ovar-
ian cancer. BRIP1 and FAM175A are both BRCA1
interacting proteins involved in recruitment of
BRCA1 to DNA DSBs (84). The BRIP1 gene was
originally suggested to be a low-penetrant breast
cancer susceptibility gene, but, later studies sug-
gested that the risk was elevated for ovarian cancer.
Pathogenic variants in FAM175A (Abraxas) have
been identiﬁed in both breast and ovarian cancer
patients, however, currently the lifetime risk for
breast- and ovarian cancer is unknown (84). The
Mre11-Rad50-Nbs1 (MRN) complex is also neces-
sary for detection and signaling of DNA DSBs
(88). So far, only MRE11 and NBN variants have
been clinically associated to breast and ovarian can-
cer. The MRN complex activates the ATM (Ataxia
Telangiectasia-Mutated) serine/threonine protein
kinase that phosphorylates factors in the DNA
damage response including TP53, CHK2, and CtIP
(RBBP8) (89). A number of rare HBOC factors
such as BLM, RECQL, FANCC, and FANCM
may also contribute to HBOC by protecting DNA
replication forks and suppressing DNA replication
stress (84).
Amongst the DNA repair pathways, mismatch
repair (MMR) is also involved though less fre-
quently than HRR. The MMR genes MLH1,
MSH2, MSH6, and PMS2 that were originally
implicated in Lynch syndrome or hereditary non-
polyposis colorectal cancer (HNPCC), also play a
role in breast and ovarian cancer since haploinsuﬃ-
ciency of MLH1, MSH2, and PMS2 appears to
increase the risk for ovarian cancer and to a minor
extent breast cancer (90, 91). The MMR system
recognizes and repairs misincorporation of nucleo-
tides and defects in MMR results in the accumula-
tion of thousands of single nucleotide variants and
microsatellite instability (MSI) in the tumors (92).
Tumor suppressor genes, such as MRE11 and
RAD50 genes, moreover, harbor microsatellites so
impaired MMR may indirectly aﬀect the MRN
complex (93).
DNA repair is undoubtedly important in sup-
pressing HBOC, but nevertheless, additional path-
ways related to genome stability and DNA damage
response are also relevant. In this regard, cell cycle
checkpoints and cell death pathways may also be
implicated in HBOC. These pathways normally
eliminate cells with damaged DNA and haploinsuf-
ﬁciency of check-point regulators genes leads to
accumulation of mutated cells. The archetypical
check-point regulator is TP53 which coordinates
several genome stability factors. ATM, CHK2 (en-
coded by CHEK2), TP53, BRCA1–BARD1 can
block the cell cycle in G1, S and in G2 phase
© 2019 The Authors. APMIS published by John Wiley & Sons Ltd
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checkpoints (94, 95). Constitutive loss of TP53
leads to the autosomal dominant Li–Fraumeni syn-
drome (LFS) with breast cancer, sarcoma, brain
tumors, and adrenocortical carcinoma (96, 97).
TP53 is activated by the ATM kinase that phos-
phorylates CHK2, and in an amplifying step CHK2
subsequently further targets TP53 thereby promot-
ing the actions of ATM (89, 98). The clinical signif-
icance of the mechanism is illustrated by the
CHEK2 c.1100delC variant that is associated with
approximately three-fold increased risk of breast
cancer (99, 100). Taken together, cells with
impaired DNA repair and cell cycle checkpoints are
ultimately likely to gain selective proliferative
advantages.
The recent progress in next generation sequenc-
ing makes it possible to identify predisposing
genetic variants in a fast and cost-eﬀective way.
We, however, face a situation where cohort and co-
segregation data may not be available for rare vari-
ants, and it is important to investigate at the pro-
tein level, for example, by employing structural and
functional analysis for variant classiﬁcation. Since
the extensive locus heterogeneity appears to
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converge on a relatively small number of genome
maintenance pathways, we predict that such analy-
sis may become a reality within a relatively short
period of time. Unfounded classiﬁcation of genetic
variants is obviously harmful to the patient, and
great care should be taken to generate common
protocols and accreditation of the analysis to meet
clinical standards.
Whole-genome sequencing can be used to detect
an impairment in two of the major pathways in the
genome-maintenance system; HRR and MMR. For
detection of homolog recombination deﬁciency
(HRD) by WGS, Davies et al. recently generated a
predictor for BRCA1 and BRCA2-defecient tumor
samples. This WGS-based predictor may be well-sui-
ted for the clinical setting since the study showed a
doubling in the detection rate of HRD tumors as well
as robustness between independent biopsies and
samples, including DNA obtained from paraﬃn-
embedded tissue (101). The signature named HRDe-
tect includes base substitutions, indels and rearrange-
ments of many more genes than just BRCA1 and
BRCA2 and is trained to suite WGS derived results.
Identifying tumors that are deﬁcient in HRR,
whether it is through germline or somatic
inactivation of BRCA1 and BRCA2 is clinically
extremely relevant since these tumors are selectively
sensitive to PARPi (102, 103). For identiﬁcation of
MMR-impaired breast cancer tumors, another WGS
based mutational signature has recently been
described (104). The mutational signature is sought
to be a direct pathophysiological reﬂection of MMR
pathway abrogation that may outperform current
biomarkers and hereby increasing the sensitivity to
immune therapies; Thus, WGS should soon be
required for up-front routine clinical analysis and we
suggest an optimized diagnostic workﬂow which
allows the performance of precision medicine, Fig. 4.
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